Press Release: Zealand Pharma Announces Financial Results for the First Nine Months of 2026

Dow Jones11-12

Company announcement -- No. 56 / 2026

Zealand Pharma Announces Financial Results for the First Nine Months of 2026

Advancing at pace towards Metabolic Frontier 2030: petrelintide in Phase 3, survodutide moving towards regulatory filings, positive CHMP opinion for Zeydovio(TM) , and new modalities for next wave

   -- Announced positive topline results from Phase 2 ZUPREME-2 trial with 
      petrelintide and initiated a registrational Phase 3 program, marking a 
      defining step toward establishing petrelintide as a future first-choice 
      therapy for people living with overweight or obesity. 
   -- Boehringer Ingelheim presented positive results from the SYNCHRONIZETM-2 
      and SYNCHRONIZETM-CVOT trials with survodutide, demonstrating clinically 
      meaningful weight loss and improvements in glycemic control in people 
      with overweight or obesity and type 2 diabetes and a favorable 
      cardiovascular safety profile compared to placebo, and is moving forward 
      with global regulatory submissions in obesity in 2027. 
 
   -- Received positive CHMP opinion for ZeydovioTM (glepaglutide), the first 
      major advancement in short bowel syndrome treatment in Europe in over a 
      decade. 
 
   -- Opened new research hub in Cambridge, Massachusetts, and entered a 
      collaboration and license agreement with Generate Biomedicines to develop 
      AI-engineered protein therapeutics for metabolic diseases, broadening 
      Zealand Pharma's modality capabilities. 

Copenhagen, Denmark, November 12, 2026 -- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, today announced the interim report for the nine months ended September 30, 2026, and provided a corporate update.

Executing on Metabolic Frontier 2030

Adam Steensberg, President and Chief Executive Officer at Zealand Pharma said:

"This quarter, we made progress on every commitment in our Metabolic Frontier 2030 strategy. With positive ZUPREME-2 results and Phase 3 initiations, petrelintide moves closer to offering a differentiated treatment option and weight management experience. Boehringer Ingelheim finalized the extensive Phase 3 program with survodutide in obesity, reinforcing its strong metabolic profile and demonstrating preferential visceral and liver fat reductions while preserving muscle mass. We also progressed our novel Kv1.3 ion channel blocker and received a positive CHMP opinion for glepaglutide in short bowel syndrome.

At the same time, we are building what comes next. Our new Cambridge research hub and collaboration with Generate Biomedicines expand what we can discover and develop. By combining advanced modelling and AI-driven design with our deep metabolic health expertise, we are building a platform to move faster from idea to clinic and deliver 10 clinical programs by 2030."

Key financial results for Q3 2026 year-to-date

 
DKK million             Q3-26 YTD  Q3-26 YTD 
----------------------  ---------  --------- 
Revenue                     4,529      9,146 
----------------------  ---------  --------- 
Operating expenses, 
 excl. OOI(1)              -1,893     -1,479 
----------------------  ---------  --------- 
Operating expenses(1)      -1,262     -1,675 
----------------------  ---------  --------- 
Operating profit            3,267      7,470 
----------------------  ---------  --------- 
Net financial items           343        -62 
----------------------  ---------  --------- 
Profit for the period       3,469      6,834 
----------------------  ---------  --------- 
 
 
                   Sep-30,  Dec-31, 
DKK million          2026     2025 
-----------------  -------  ------- 
Cash position(2)    13,509   15,109 
-----------------  -------  ------- 
 

Notes:

1. Operating expenses consist of R&D, S&M, G&A and Other operating items (OOI).

2. Cash position includes cash, cash equivalents and marketable securities.

Q3 2026 Highlights and Recent Developments

Obesity

   -- Petrelintide, amylin analog. Zealand Pharma reached a key milestone with 
      the initiation of the global Phase 3 registrational program, together 
      with Roche, to address important unmet medical needs in chronic weight 
      management. The program consists of three registrational trials and is 
      expected to enroll approximately 7,000 participants in total. 
 
   -- Petrelintide, amylin analog. The company reported positive topline 
      results from the Phase 2 ZUPREME-2 trial in people with overweight or 
      obesity and type 2 diabetes. Petrelintide delivered up to 9.2% weight 
      loss at week 28 and clinically meaningful HbA1c reductions of up to 0.65% 
      from a mean HbA1c at baseline of 7.7% (specified from 8.0% in original 
      company announcement). Safety and tolerability profile of petrelintide 
      was consistent with that seen in the Phase 2 ZUPREME-1 trial. 
   -- Survodutide, glucagon/GLP-1 receptor dual agonist. Boehringer Ingelheim 
      presented results from the SYNCHRONIZETM-CVOT Phase 3 trial in people 
      living overweight or obesity with established cardiovascular disease 
      (CVD), chronic kidney disease, and/or at least two-weight related 
      complications or risk factors for CVD. As the first glucagon/GLP-1 dual 
      agonist, survodutide demonstrated a favorable cardiovascular safety 
      profile compared to placebo alongside significant cardiometabolic 
      benefits. 
   -- Survodutide, glucagon/GLP-1 receptor dual agonist. Boehringer Ingelheim 
      presented results from the SYNCHRONIZETM-2 Phase 3 trial in people living 
      with overweight or obesity and type 2 diabetes. The trial met its primary 
      endpoints and showed up to 13.1% body weight reduction in a population in 
      which weight loss is typically more challenging along with improvements 
      in key markers of cardiometabolic health, including clinically meaningful 
      reductions in HbA1c and waist circumference. 
   -- Survodutide, glucagon/GLP-1 receptor dual agonist. Boehringer Ingelheim 
      expanded the development program for survodutide with the initiation of a 
      Phase 3 trial in people with type 2 diabetes and planned initiation of 
      three Phase 3b trials to address key unmet needs in people living with 
      obesity and real-world care. 
   -- ZP6590, GIP receptor agonist. Zealand Pharma initiated a first-in-human 
      Phase 1 clinical trial with ZP6590. 

Chronic inflammation

   -- ZP9830, Kv1.3 Ion Channel Blocker. Zealand Pharma initiated a Phase 1b 
      trial with efficacy endpoints, investigating ZP9830 in people with 
      psoriasis. 
 
   -- ZP9830, Kv1.3 Ion Channel Blocker. Zealand Pharma reported positive 
      topline data from the MAD part of the Phase 1a clinical trial. Multiple 
      doses of ZP9830 were well tolerated with no serious or severe adverse 
      events or dose-limiting safety findings observed. Pharmacokinetics 
      parameters support continued development of ZP9830 in trials of longer 
      duration. 

Rare diseases

   -- Glepaglutide in SBS. Zealand Pharma announced that the CHMP of the 
      European Medicines Agency (EMA) has recommended the approval of 
      ZeydovioTM (glepaglutide) for the treatment of short bowel syndrome 
      (SBS). 

Corporate

   -- Zealand Pharma entered into a collaboration and license agreement with 
      Generate Biomedicines to develop protein therapeutics, broadening Zealand 
      Pharma's modality capabilities and opening new approaches for 
      polypharmacology for innovative therapeutics. The collaboration will 
      combine Zealand Pharma's metabolic health expertise with The Generate 
      Platform, which integrates generative AI with high-throughput 
      experimental validation. 
   -- Zealand Pharma announced opening of its new research hub in Cambridge, 
      Massachusetts. The 53,600 RSF (approximately 5,000 m2) site expands the 
      company's research capabilities beyond its core peptide expertise into 
      hybrid modalities, including biologics such as antibody peptide 
      conjugates. The platform will be built around automation and advanced 
      modeling techniques to accelerate medicine creation. 
   -- Zealand Pharma completed the share buy-back program, initiated on May 7, 
      2026. During the program, a total of 4,408,500 shares were repurchased at 
      a total gross value of DKK 1,300 million. 
   -- Zealand Pharma entered into a USD 100 million royalty purchase and sale 
      agreement with Royalty Pharma for rusfertide. 

Upcoming events in 2026

Obesity

   -- Petrelintide/enicepatide (CT-388), amylin+GLP-1/GIP fixed-dose 
      combination. Zealand Pharma and Roche expect to initiate the Phase 2 
      ZYNERGY trial in people with overweight or obesity in Q4 2026. 

Rare diseases

   -- Glepaglutide in SBS. Zealand Pharma expects a final decision on the EU 
      Marketing Authorization Application in Q4 2026. In parallel, the company 
      is engaging in partnership discussions for future commercialization of 
      glepaglutide for SBS. 
   -- Dasiglucagon in CHI. In Q4 2026, Zealand Pharma expects to resubmit the 
      New Drug Application (NDA) for congenital hyperinsulinism (CHI) to the 
      U.S. FDA. The submission will encompass both the three weeks use of 
      dasiglucagon (Part 1 of the original NDA) as well as the use beyond three 
      weeks (Part 2 of the original NDA). 

Financial guidance for 2026

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment